GlassScriptPhysician profile
Juliana Elyse Gilbert
NPI 1184062481
$7,655.95
in general payments reported to CMS, 2019-2025
31 companies · $1,853 in 2025
The $1,853 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $892 · 2020: $303 · 2021: $388 · 2022: $1,010 · 2023: $1,669 · 2024: $1,541 · 2025: $1,853.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,895 · Education: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,894.98 |
| Education | $167.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,906.62 | 2019-2025 | |
| Janssen Biotech, INC. | $1,082.83 | 2019-2025 | Tremfya, Stelara, Simponi |
| Novartis Pharmaceuticals Corporation | $736.80 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $539.83 | 2019-2025 | Dupixent |
| Amgen INC. | $520.30 | 2019-2025 | Otezla, Otezla |
| Ucb, INC. | $397.35 | 2020-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $331.01 | 2022-2025 | Sotyktu |
| Pfizer INC. | $298.76 | 2019-2024 | |
| Galderma Laboratories, L.P. | $286.56 | 2022-2025 | Nemluvio, Aklief |
| Lilly USA, LLC | $284.87 | 2019-2024 | Taltz, Olumiant |
| Leo Pharma INC. | $229.59 | 2019-2025 | Adbry |
| Arcutis Biotherapeutics, INC. | $189.99 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $120.24 | 2019-2024 | Odomzo, Blu-U |
| Genzyme Corporation | $107.30 | 2019-2024 | |
| Dermavant Sciences, INC. | $81.53 | 2023-2024 | Vtama |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $65.56 | 2024-2025 | Acthar |
| Incyte Corporation | $63.91 | 2021-2024 | Opzelura |
| Celgene Corporation | $63.47 | 2019 | |
| Verrica Pharmaceuticals INC. | $45.44 | 2024-2025 | Ycanth |
| Biofrontera INC. | $43.44 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $41.31 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.59 | 2023 | Spevigo |
| Ani Pharmaceuticals, INC. | $33.02 | 2025 | Purified Cortrophin Gel |
| Mayne Pharma Commercial LLC | $31.69 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $22.35 | 2024 | Givlaari |
| Mylan Institutional INC. | $20.12 | 2023 | Hulio |
| Epi Health, LLC | $19.61 | 2022 | |
| Dermira, INC. | $16.77 | 2020 | |
| Organon LLC | $14.76 | 2023-2025 | Hadlima, Vtama |
| Triad Life Sciences INC. | $13.93 | 2022 | |
| Prugen, INC. Pharmaceuticals | $7.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juliana Gilbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.